KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Capital Employed: 2009-2025

Historic Return on Capital Employed for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to 0.26%.

  • Acadia Pharmaceuticals' Return on Capital Employed rose 7.00% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year increase of 7.00%. This contributed to the annual value of 0.40% for FY2024, which is 58.00% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Return on Capital Employed of 0.26% as of Q3 2025, which was down 6.28% from 0.28% recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Return on Capital Employed high stood at 0.34% for Q4 2024, and its period low was -0.48% during Q4 2022.
  • In the last 3 years, Acadia Pharmaceuticals' Return on Capital Employed had a median value of 0.04% in 2024 and averaged 0.01%.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Return on Capital Employed fell by 20bps in 2022, and later skyrocketed by 55bps in 2024.
  • Acadia Pharmaceuticals' Return on Capital Employed (Quarterly) stood at -0.28% in 2021, then declined by 20bps to -0.48% in 2022, then skyrocketed by 31bps to -0.17% in 2023, then skyrocketed by 50bps to 0.34% in 2024, then grew by 7bps to 0.26% in 2025.
  • Its Return on Capital Employed stands at 0.26% for Q3 2025, versus 0.28% for Q2 2025 and 0.27% for Q1 2025.